Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Total Liabilities (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Total Liabilities for 11 consecutive years, with $56.2 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 39.76% to $56.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.2 million through Dec 2025, down 39.76% year-over-year, with the annual reading at $56.2 million for FY2025, 39.76% down from the prior year.
  • Total Liabilities hit $56.2 million in Q4 2025 for Voyager Therapeutics, down from $68.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $148.3 million in Q1 2022 to a low of $56.2 million in Q4 2025.
  • Historically, Total Liabilities has averaged $102.3 million across 5 years, with a median of $100.6 million in 2022.
  • Biggest five-year swings in Total Liabilities: plummeted 58.2% in 2021 and later soared 46.05% in 2022.
  • Year by year, Total Liabilities stood at $98.8 million in 2021, then increased by 1.55% to $100.3 million in 2022, then increased by 14.58% to $115.0 million in 2023, then decreased by 18.85% to $93.3 million in 2024, then crashed by 39.76% to $56.2 million in 2025.
  • Business Quant data shows Total Liabilities for VYGR at $56.2 million in Q4 2025, $68.5 million in Q3 2025, and $78.2 million in Q2 2025.